Incyte Deepens AI Drug Discovery Bet in $120 Million Deal
WILMINGTON, DE — Incyte (Nasdaq: INCY) is expanding its partnership with biotechnology software firm Genesis Molecular AI in a deal worth $120 million upfront, giving the company broader access to …
Incyte Deepens AI Drug Discovery Bet in $120 Million Deal Read More